New Jersey, United States, Jan 15, 2023 /DigitalJournal/ AI can aid in structure-based drug discovery by predicting 3D protein structure as the design conforms to the chemical environment of the target protein site, thus helping to predict the effect of a compound on the target as well as safety considerations prior to their synthesis or manufacture. Growing demand for the discovery and development of new drug therapies and increasing manufacturing capabilities in the life science industry are driving the demand for artificial intelligence (AI) based solutions in drug discovery processes. Manufacturers in the life science industry are constantly focused on replenishing their product pipelines as the majority of big sellers drop their patents. The global Artificial Intelligence (AI) in Drug Discovery Market is expected to grow at a Massive CAGR of 29.5% during the forecasting period of 2022 to 2029. The Artificial Intelligence (AI) in Drug Discovery Market research report provides all the information related to the industry.

Visiongain has published a new report entitled the Artificial Intelligence (AI) in Drug Discovery 2022-2032. It includes profiles of Artificial Intelligence (AI) in Drug Discovery and Forecasts Market Segment by Offering, (AI Software, AI Services) Market Segment by Technology, (Deep Learning, Supervised Learning, Reinforcement Learning, Unsupervised Learning, Other Technology) Market Segment by Applications, (Oncology, Infectious Diseases, Neurological Disorders, Metabolic Diseases, Cardiovascular Diseases, Other Applications) Market Segment by Type, (Target Identification, Molecule Screening, Drug Design and Drug Optimization, Preclinical and Clinical Testing) PLUS COVID-19 Impact Analysis and Recovery Pattern Analysis (V-shaped, W-shaped, U-shaped, L-shaped) Profiles of Leading Companies, Region and Country. The global artificial intelligence (AI) in drug discovery market was valued at US$791 million in 2021 and is projected to grow at a CAGR of 30.7% during the forecast period 2022-2032. AI makes use of the most recent developments in biology and computation to create cutting-edge drug discovery algorithms. AI has the potential to level the playing field in drug research, with to rapid increases in computing capacity and lower processing costs.

Dublin, Aug. 12, 2022 (GLOBE NEWSWIRE) — The "Global Artificial Intelligence (AI) in Drug Discovery Market (2022-2027) by Offering, Drug Type, …

The growth of this Artificial Intelligence in Drug Discovery Market is driven by the growing need to control drug discovery & development costs, …

4.3 Deep Learning Segment Accounted for the Largest Market Share in 2021. 4.4 North America is the Fastest-Growing Regional Market for AI in Drug …

According to the new market research report "AI in Drug Discovery Market by Offering (Software, Service), Technology (Machine Learning, …

Market Research Future (MRFR) is a global market research company that takes pride in its services, offering a complete and accurate analysis with regard to diverse markets and consumers worldwide. Market Research Future has the distinguished objective of providing the optimal quality research and granular research to clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help answer your most important questions.

According to Markets and Markets, the global AI drug discovery market is projected to reach $ 1,434 million by 2024 from $ 259 million in 2019, at a CAGR of 40.8% during the forecast period 2019–2024. For example, BioXcel Therapeutics, Inc. (Nasdaq: BTAI) is a clinical-stage company utilising AI drug discovery approaches in neuroscience and immuno-oncology and has an emerging drug named BXCL501, that is an orally dissolving thin film formulation of dexmedetomidine, a selective alpha-2a receptor agonist for the treatment of agitation associated with neuropsychiatric disorders (Via Finance Yahoo). BioXcel Therapeutics has observed anti-agitation results in multiple clinical studies with BXCL501 including: SERENITY I for schizophrenia related agitation, SERENITY II for bipolar disorder related agitation and TRANQUILITY for dementia related agitation. Accordingly, BXCL501 has been granted Breakthrough Therapy designation for the acute treatment of agitation associated with dementia and Fast Track designation for the acute treatment of agitation associated with schizophrenia, bipolar disorders and dementia. Moreover, BioXcel recently received acceptance of its New Drug Application for BXCL501 for the acute treatment of agitation associated with schizophrenia and bipolar disorders.

The large scale Artificial Intelligence (AI) in Drug Discovery business report is an aid to assess the reaction of the consumers to the packaging of the firm and to make packaging as attractive as possible. This global Market report makes it easy to know the transportation, storage and supply requirements of its products. A lot of hard work has been involved while generating this Market research report where no stone is left unturned. It brings into focus public demands, competencies and the constant growth of the working industry, vibrant reporting, or high data protection services while analyzing Market information. The persuasive Artificial Intelligence (AI) in Drug Discovery report highlights a wide-ranging evaluation of the Market's growth prospects and restrictions.

Artificial Intelligence (AI) in Drug Discovery Market Research report is a professional and in-depth study on the market size, growth, share, trends, as well …